Amgen to acquire American biopharma company ChemoCentryx for $3.7bn

Amgen has agreed to acquire ChemoCentryx, a biopharma company engaged in developing medications for inflammatory and autoimmune diseases and cancer, in an all-cash deal worth ... Read More